NL-OMON40611已完成不适用
A phase I, randomised, double-blind, placebo-controlled study in patients with amyotrophic lateral sclerosis to further assess the safety and tolerability of intracerebroventricular administration of sNN0029 infusion solution. - Study of sNN0029 in ALS patients.
ewron Sweden AB0 个研究点目标入组 9 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
Trial ended prematurely
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Ability to understand and provide written informed consent to participate in the trial before any trial-related procedures are conducted.
- •2. Clinical diagnosis of ALS classified as definite, or probable with or without additional laboratory evidence, according to the revised World Federation of Neurology (WFN) El Escorial criteria.
- •3. Male or female aged 18 to 75 years inclusive.
- •4. If patients are being treated with riluzole, they must have been on a stable dose for at least the past 30 days prior to screening.
- •5. The patient is, in the opinion of the investigator, medically fit to undergo the surgery required for stereotactic implantation of the catheter and infusion pump.
排除标准
- •1. Impaired respiratory function judged to pose a risk to the patient during anaesthesia for the device implantation.
- •2. Hypertension defined as blood pressure >160 mmHg systolic or >90 mmHg diastolic.
- •3. Values for coagulation parameters including platelet count, normalised prothrombin complex (PK-INR), activated partial thromboplastin time (APTT) outside normal ranges.
- •4. Ophthalmological examination including fundus photography, visual acuity by Early Treatment in Diabetic Retinopathy Study (ETDRS) and perimetry, with any clinically significant findings that imply safety concerns for this study.
- •5. Diagnosis of diabetes mellitus.
- •6. History of structural brain disease other than ALS, including tumours and hyperplasia.
- •7. An MRI of the brain and cervical spine, and an MRA of the brain with findings of tumours or potential sources of pathological bleedings, or abnormality that may interfere with the assessments of safety or efficacy or that would, in the judgment of the investigator, represent a surgical risk to the patient. If an MRI and/or MRA has been performed within 1 month prior to screening, the results from that examination can be used.
- •8. Any disorder that precludes a surgical procedure (e.g., signs of sepsis or inadequately treated infection), alters wound healing (e.g., including bleeding disorders), or renders chronic i.c.v. delivery or device implants medically unsuitable.
- •9. Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that cannot be not managed optimally due to:
- •i. anatomical factors at or near the implant site (e.g., vascular abnormalities, neoplasms, or other abnormalities),
- •ii. underlying disorders of the coagulation cascade, platelet function, or platelet count (e.g., haemophilia, Von Willebrand*s disease, liver disease, or other medical conditions)
- •iii. administration of any antiplatelet or anticoagulant medication in the preoperative period
- •10. A personal history of thromboembolic disease. A family history of thromboembolic disease will prompt a laboratory assessment to exclude hereditary liability before the patient is declared eligible.
- •11. Presence of additional risk factors for thromboembolism such as obesity (BMI>35) or use of oestrogens including combined contraceptive pills.
- •12. Presence of an implanted shunt of the drainage of CSF or an implanted CNS catheter.
- •13. Clinically significant abnormalities in haematology or clinical chemistry parameters as assessed by the investigator.
- •14. Serological evidence of Hepatitis B virus (HBV), Hepatitis C virus (HCV) or Human immunodeficiency virus (HIV)
- •15. Ongoing medical condition that according to the investigator would interfere with the conduct and assessments in the study. Examples are medical disability (e.g., severe degenerative arthritis, compromised nutritional state, peripheral neuropathy) that would interfere with the assessment of safety and efficacy of investigational product or device performance, or would compromise the ability of the patient to undergo study procedures (e.g., MRI), or to give informed consent.
- •16. Participation in another clinical trial with an investigational drug or device within 3 months prior to screening visit.
- •17. For women only: pregnant, breast feeding and/or for fecund women unwillingness to use
- •adequate contraception during the trial such as:
- •- Established use of oral, injected or implanted hormonal meth
研究者
相似试验
已完成
不适用
A phase I randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of NPT189 in healthy subjectsAmyloidosisNL-OMON48151Proclara Biosciences, Inc.24
已完成
不适用
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, First in Man, Single Escalating Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GAL-475 in Healthy Male Volunteers and Male Subjects with Sleep Apneasleep disorderSleep apneaNL-OMON55229eurim Pharmaceuticals Ltd.36
已完成
3 期
A randomized, double-blind, placebo-controlled intervention study to assess the therapeutic effect of an extensively hydrolyzed infant formula with an added synbiotic mixture in infants with atopic dermatitis.eczema1003871610040785atopic dermatitisNL-OMON39465Danone Research - Centre for Specialised Nutrition144
已完成
2 期
A randomized, placebo-controlled, double-blind, parallel-group, multi-center, exploratory dose-response study to assess the efficacy and safety of different oral doses of BAY1128688 in women with symptomatic endometriosis over a 12-week treatment periodpain during intercourse ('dyspareunia') and non-cyclic pelvic pain.Well-accepted lay language synomyms for endometriosis are not known to us. Endometriosis describes the presence of endometrium elsewhere than in the lining of the uterus. It is associated with pelvic pain during menstruation called 'dysmenorrhea'10038612NL-OMON46660Bayer5
已完成
不适用
A double-blind, placebo-controlled, randomized clinical pharmacology study to evaluate the prevention effect and the recovery-promoting effect of a single subcutaneous administration of GYM329 on disuse muscle atrophy in healthy male volunteers.Muscular Atrophy10028302NL-OMON54969Chugai Pharmaceutical Co., Ltd.48